Loading
companiesCompany
Therapixel
Therapixel's MammoScreen software uses artificial intelligence to point out suspicious areas on mammograms and score how likely they are to be cancer, helping radiologists in the US and Europe read screening exams.
Overview
Therapixel, founded in 2013 and headquartered in Nice with offices in Paris and Chicago, develops MammoScreen, an AI reading aid for screening mammography that detects suspicious lesions and calcifications and assigns a malignancy likelihood score. MammoScreen received FDA 510(k) clearance for 2D mammography in July 2020 (K192854) after a multi-reader multi-case study showing improved radiologist detection, and for digital breast tomosynthesis in November 2021; version 2.0 added prior-exam comparison in 2022 and the product is CE marked. A prospective study of AI within second reading in the French screening programme began in October 2022. In 2025 the company announced deployment across more than 150 Onsite Women's Health locations and adoption by Mayo Clinic. A EUR 15 million Series B closed in May 2022, co-led by Crédit Mutuel Innovation and CapHorn, for over EUR 20 million raised in total.
Headquarters
Nice, FR
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Series B · EUR 15 million, co-led by Crédit Mutuel Innovation and CapHorn, May 2022; over EUR 20 million raised since founding. | 2022 | undisclosed | therapixel.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Founded
2013
Notes
top- Earlier EUR 5 million round (2019) is only referenced via a third-party article on the press page so it is not recorded.
Similar pages
- CompanyVara
Shares Mammography & tomosynthesis, AI in radiology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- CompanyVolpara Health
Shares Mammography & tomosynthesis, AI in radiology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- CompanyKheiron Medical Technologies
Shares Mammography & tomosynthesis, AI in radiology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- JournalJournal of breast imaging
Shares Mammography & tomosynthesis, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- TreatmentProFound AI (iCAD)
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- TreatmentTranspara
Shares Mammography & tomosynthesis, AI in radiology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- CompanyiSono Health
Shares AI in radiology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- CompanyiCAD (RadNet)
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
Software in use
The software of oncology →Commercial and regulated products that this organisation sells. Each card says what is behind it: a regulator's database, the literature, a public body's list, or only the company's own words. Listing is not endorsement, and a clearance is a regulatory fact, not a clinical one.
A mammography reading algorithm that scores each breast and marks findings, with a separate density product.